Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

TOP - February 2017, Vol 10, No 1

Patients receiving allogeneic hematopoietic stem-cell transplant (HSCT) have high rates of vancomycin-resistant enterococci (VRE) upon admission for transplantation.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
The relative lack of progress in the treatment of malignant pleural mesothelioma is in marked contrast to developments in the treat­ment of lung cancer overall, but several ongoing studies using different immune-based therapies have shown promise in the treatment of this type of cancer.
A persistent medi­­cation safety issue is getting the attention it has long deserved. In an effort to save lives related to the accidental intrathecal dosing of vincristine, the National Comprehensive Cancer Network (NCCN) has launched a program called “Just Bag It: The NCCN Campaign for Safe Handling of Vincristine."
The Mass General Cancer Center is among the leading cancer care providers in the United States, and is a National Cancer Institute–designated comprehensive cancer center as part of the 7-member Harvard Medical School consortium.
Limited real-world evidence is available to describe the recent trends in multiple myeloma (MM) treatment costs and outcomes.
Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile when used in combination with bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.
In 2015, the combination of bortez­omib, lenalidomide, and dexamethasone was shown to improve survival outcomes versus lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma. However, this triplet therapy also increased patients’ risk for severe peripheral neuropathy.
Daratumumab therapy is successful in patients with multiple myeloma who have received ≥3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug (IMiD), or whose disease is double-refractory to those other drugs.
In the long-term, phase 1b/2 PCYC-1102 clinical trial, single-agent ibrutinib, the first FDA-approved once-daily Bruton’s tyrosine kinase inhibitor, showed efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including patients with deletion (del)17p.
Page 2 of 3
Results 11 - 20 of 29